Sex-specific differences in drug treatment;Geschlechtsspezifische unterschiede bei arzneimitteln

Therapeutische Umschau

Volumn 64, Issue 6, 2007, Pages 325-329

  Thürmann, Petra A ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; CYTOCHROME P450; THALIDOMIDE;

CARDIOVASCULAR DISEASE; DEPRESSION; DRUG INDUCED DISEASE; ELECTROPHYSIOLOGY; GLUCURONIDATION; HEALTH SURVEY; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; QT PROLONGATION; REVIEW; SEX DIFFERENCE; TORSADE DES POINTES;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS;

EID: 34250904158     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.64.6.325     Document Type: Review

References (22)

1. Thürmann PA. Geschlechtsspezifische Unterschiede bei der Pharmakokinetik und -dynamik von Arzneimitteln. Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 2005; 48: 536-40.
2. Merkatz RB.Women in clinical trials of new drugs. A change in the Food and Drug Administration policy. N Engl J Med 1993; 329: 292-6.
3. Evelyn B, Toigo T, Banks D, et al. Women's participation in clinical trials and gender-related labeling. A review of new molecular entities approved 1995-1999. FDA, August 24, 2001. www.fda.gov/cder/reports/womens_health/ women_clin_trials.htm
4. Fleisch J, Fleisch MC, Thurmann PA. Women in early-phase clinical drug trials: have things changed over the past 20 years? Clin Pharmacol Ther 2005; 78: 445-52.
5. Tenter U, Thurmann PA. References to sex-specific differences of drug effects in German SPCs for new entities from 1999-2004. Int J Clin Pharmacol Ther 2006; 44: 531 (abstr.).
6. Martin R, Biswas PN, Freemantle SN, et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-11.
7. Thurmann PA. Geschlechtsspezifische Aspekte in der Pharmakotherapie: was ist gesichert? Z Allg Med 2006; 82: 380-4.
8. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.
9. Thurmann PA, Haack S, Werner U, et al. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 2006; 80: 551-3.
10. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20: 1491-8.
11. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
12. Berger J, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006; 295: 306-13.
13. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243-52.
14. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11.
15. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24: 575-85.
16. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003; 160: 1643-50.
17. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-52.
18. Kornstein SG, Sloan DM, Thase ME. Gender-differences in depression and treatment response. Psychopharmacol Bull 2002; 36: 99-112.
19. Seeman MV. Gender differences in prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161: 1324-33.
20. Aichhorn W, Whitworth A, Weiss EM, Marksteiner J. Second-generation antipsychotics. Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf2006; 29: 578-98.
21. Pinn VW. Sex and gender factors in medical studies. Implications for health and clinical practice. JAMA 2003; 289: 397.
22. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001; 286: 708-13.